
Corline Biomedical Q1 - Exciting quarters ahead

Redeye provides an update following Corline's Q1 2025 report. Both sales and costs came in slightly below our predictions, but overall, the report was largely in line with our projections. Looking ahead, we emphasise that Corline is entering a critical period, with particular focus on Kardium's upcoming launch of the CHS-coated Globe system. Following the report, we have made only minor adjustments to our 2025e estimate.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Corline Biomedical Q1 - Exciting quarters ahead